Outbreak risks, cases, and costs of vaccination strategies against wild poliomyelitis in polio-free settings: a modelling study

Megan Auzenbergs[1,2], Kaja Abbas[1,2], Arie Voorman[3,4], Corey Peak[4], Mark Jit, Kathleen M O'Reilly[1,2]

[1] Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK
[2] Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK
[3] Institute for Disease Modelling, Seattle, WA, USA
[4] Bill and Melinda Gates Foundation, Seattle, WA, USA

Corresponding author:
Megan Auzenbergs
Megan.auzenbergs@lshtm.ac.uk

Abstract

Background

Polio eradication was threatened in 2022 by importation of wild poliovirus serotype 1 into Malawi with subsequent international spread, representing the first wild polio cases in Africa since 2014. Preventing importations and spread of wild poliovirus is critical, and dependent on population immunity provided through routine immunisation and supplementary immunisation activities (SIAs). However, the scale of preventative SIAs has reduced in recent years due to financial constraints.

Methods

We developed a mathematical model of polio transmission dynamics to evaluate the probability of an outbreak, expected number of poliomyelitis cases, and the costs associated with vaccination delivery through routine immunisation (RI), outbreak response SIAs (oSIAs) and preventative SIAs (pSIAs). Across varying levels of routine immunisation coverage, we explore three key strategies: RI+oSIAs, RI+oSIAs+annual pSIAs, and RI+oSIAs+biannual pSIAs.

Results

The annual pSIA strategy (RI+oSIAs+annual pSIAs) had higher costs but greater probability of no outbreaks: under our model assumptions, annual pSIAs result in 80% probability of no outbreaks when routine immunisation coverage ≥50%. The biannual pSIA strategy (RI+oSIAs+biannual pSIAs) costs less and averts more outbreaks than RI+oSIAs, but RI coverage ≥65% was required to achieve equivalent risk of no outbreaks. The strategy with no pSIAs (RI+oSIAs) had the lowest costs but required ≥75% RI coverage to achieve equivalent risk of no outbreaks.

Conclusion

Prioritisation of pSIAs must balance outbreak risk against implementation costs, ideally favouring the smallest manageable outbreak risk compatible with elimination. We infer that there are few short-term risks due to population immunity from RI, but without pSIAs, long-term risks accumulate and can result in outbreaks with potential for international spread. We do not consider the costs of further delaying the eradication timeline or societal implications of outbreaks, both of which emphasise the need for pSIAs.

Introduction

In 2019, the African Region was certified free from endogenous transmission of wild poliovirus (WPV), with the last case reported in Nigeria in July 2014 (1). However, in early 2022, Malawi and Mozambique reported WPV serotype 1 (WPV1) cases, linked to ongoing circulation in Pakistan (2, 3). The geographic distribution and genetic linkage of these WPV1 cases suggest missed transmission of an unknown geographic extent (2). These WPV1 cases highlight the importance of ensuring high and homogeneous levels of population immunity despite decreasing global incidence and elimination within the African continent (4). Historically, WPV1 outbreaks in Africa had a varied epidemiology—ranging in size from a few cases to explosive outbreaks that resulted in international spread and wide-scale outbreak responses. This variation can be attributed to population exposure to circulating virus and serotype-specific population immunity against poliovirus, among other factors (5).

Since 2016, the recommended routine immunisation schedule is with bivalent oral polio vaccine (bOPV) and at least 1 dose of the inactivated polio vaccine (IPV) to provide population immunity. However, variable routine immunisation coverage leads to differential population immunity in different countries. The joint assessment of immunization coverage by UNICEF and WHO (WUENIC) estimated in 2021 routine vaccine coverage in Malawi and Mozambique was 93% and 61%, respectively. Also, low levels of population immunity persist in other areas, such as Liberia, where a recent study demonstrated poliovirus antibody seroprevalence was only 60% against serotype 1 (6). Further, the number of circulating vaccine derived poliovirus serotype 1 (cVDPV1) outbreaks has increased since 2022, suggesting that population immunity against this serotype has declined in some areas despite a rise in IPV coverage (which is expected to reduce the incidence of paralysis but has limited impact on transmission) (7).

The Global Polio Eradication Initiative (GPEI) is responsible for the coordination of activities to support polio eradication. The activities include surveillance for acute flaccid paralysis (AFP) caused by polio infection, environmental surveillance (ES) for poliovirus, and providing polio vaccinations through both supplementary immunisation activities (SIAs) and routine immunisation (through the Expanded Programme for Immunisation (EPI)). The SIAs aim to vaccinate hard-to-reach children otherwise missed by RI (8). Despite an annual expenditure of hundreds of millions of USD, decision makers within polio eradication often must make difficult decisions in resource allocation. The global budget has remained relatively stable over the last decade with noted decreases in the last three years. Alongside, the frequency of preventative supplementary immunisation activities (pSIAs), which aim to strengthen population immunity and prevent the frequency and impact of outbreaks has decreased in almost all countries in Africa since 2017 (Figure 1) (9). However, the annual costs for vaccination and programmatic activities such as antiviral development and vaccine stockpiling carried out by GPEI have increased considerably (10, 11).

Figure 1. Historical pSIAs and RI coverage for 30 African countries *(A) Average number of pSIAs per year from 2013-2017 and 2018-2022 and (B) year of last pSIA and WUENIC estimates of DTP3 coverage. Preventative SIAs were defined as either a national or subnational immunisation day (NID, SNID) with bOPV (or tOPV pre-2016) and did not occur within 365 days of a WPV1 or VDPV1 detection, to distinguish historic pSIAs from oSIAs. Any SIAs that occurred within 365 days of a WPV1 or VDPV1 outbreak were not included in the pSIA count. CAR= Central African Republic; DRC = Democratic Republic of the Congo*

Since the World Health Assembly's 1988 resolution to eradicate polio by the year 2000, economic analyses have informed strategies to progress towards this goal. These studies inferred that polio eradication is cost-effective, assuming all vaccination stops following certification of global eradication

(12-14). Together, polio vaccination and achieving global polio eradication are estimated to save approximately 40 million DALYs by 2050 (15). However, existing economic analyses do not consider the cost-effectiveness of specific operational decisions for preventative SIAs (pSIAs) and outbreak response SIAs (oSIAs) given a shrinking budget (16) or are outdated and apply to limited geographies (17). The distinction between pSIAs and oSIAs is important because pSIAs and oSIAs have different strategic goals and funding approaches, and programmatic decisions between vaccination strategies are required imminently, not just in the future context of OPV cessation. We aim to compare strategies of differing frequency of pSIAs to that of RI and oSIAs to identify at what levels of RI the risks of outbreaks and polio cases may outweigh the associated costs of implementing pSIAs. This is an evidence gap identified by stakeholders that is important to address if and when we approach the final few years of WPV1 transmission and start to consider OPV cessation.

Methods

The GPEI works with a fixed annual budget for their operations, based on donations from stakeholders. This budget is used to support the GPEI's objectives, including the global interruption of poliovirus transmission. Operationally, the planned budget is further divided into planned SIAs and outbreak response, and additional budget lines (not considered further in this study). Outbreak response includes oSIAs, and planned SIAs are either preventive in nature or used in endemic settings (not consider further here); pSIAs lower the risk of outbreaks due to the increase in population immunity. oSIAs include vaccination following a detected case (or at least two separate environmental detections that were collected from two different ES sites with no overlap in catchment area or collected from the same ES site at least two months apart (18)) and aim to raise population immunity in the affected areas to stop transmission. Operationally, pSIAs and oSIAs differ both in the target populations for vaccination as well as the funding and planning for activities – oSIAs must be implemented quickly and require more resource for rapid mobilisation. In this study, we consider only the risks of WPV1 outbreaks in a polio-free setting; the bOPV and IPV used in RI provide immunity against serotype 1. SIAs using bOPV also provide protection against infection as well as protection against paralysis. Outbreaks of vaccine-derived poliovirus serotype 2 require alternative vaccines and assumptions and are therefore beyond the scope of this analysis.

We evaluated different pSIA vaccination strategies in addition to RI and oSIAs for a population of 8 million children under five years of age, reflecting an average population size of a LMIC in Sub-Saharan Africa. We estimated costs alongside health benefits and risks for each vaccination strategy over a five-year time-period to align with the current GPEI timeline for polio eradication. Model outputs from each strategy include: probability of an outbreak, estimated cases of paralytic poliomyelitis and VAPP, number of outbreaks and estimated disability adjusted life years (DALYs) associated with these cases (Figure 2).

Figure 2. Health benefits, risks, and costs of polio vaccination. *Schematic showing the relationships between vaccination, population immunity, paralytic poliomyelitis cases, adverse events and subsequent costs.*

Vaccination strategies

We explored three vaccination strategies (Table 1). We assume that vaccination via RI occurs in all strategies and follows a sequential immunisation schedule that includes 3 doses of bOPV given orally via drops in the mouth and 1 dose IPV administered intramuscularly or subcutaneously. The first two comparator strategies (RI+oSIAs+annual pSIAs and RI+oSIAs+biannual pSIAs) maintain the same assumptions about baseline RI coverage, but additionally include one pSIA either every year or every two years, respectively, across time.

***Table 1. Polio vaccination strategies**. RI = Routine Immunisation, oSIA = outbreak response supplementary immunisation activity, pSIA = preventative supplementary immunisation activity. An outbreak response was only conducted if a simulation had at least 1 case of paralytic polio.*

Vaccination strategy	Specification
Baseline strategy	RI + oSIAs *No preventative SIAs*
Comparator strategy 1	RI + oSIAs + *annual* pSIAs
Comparator strategy 2	RI + oSIAs + *biannual* pSIAs

In all strategies, we define an outbreak as at least one case of paralytic polio (18). An oSIA is conducted in all simulations for each strategy where at least one case was detected within any 90-day interval, in line with the median interval from notification to response as per the standard operating procedures (SOP) for polio outbreaks (18, 19). oSIAs continue until all cases are stopped over the five-year time horizon. We do not account for ES detections in this analysis. Children who were not vaccinated via RI, can receive additional doses of bOPV vaccine through either pSIAs or oSIAs. We assume that all SIAs reach 25% of children missed by RI, as prior evidence suggests that SIA coverage can be variable across locations and preliminary analysis of higher coverage for zero-dose children resulted in unrealistically high population immunity when compared to empirical data (20, 21). Appendix Table 4 includes a sensitivity analysis of different SIA assumptions.

Model structure

We developed a stochastic non-linear mathematical model to simulate polio transmission dynamics, whereby infectious individuals develop either asymptomatic or symptomatic infection, both of which are assumed to be infectious. We specify vaccine induced immunity based on OPV and IPV doses (Appendix Figure 1). In the model, children under five years of age are either susceptible, fully vaccinated and protected from poliovirus infection, or have received an incomplete vaccination series (less than 3 bOPV doses + 1 IPV dose). Each subsequent dose of vaccine corresponds to additional protection and an opportunity for a child to seroconvert and be considered fully protected from poliovirus infection. Further explanation of model compartments and transitions is in Appendix Table 1.

Time horizon and model assumptions

The modelled time horizon is five years, in line with the current GPEI strategic plan (22). The WPV1 case to infection ratio was assumed to be 1:200, which is consistent with estimates for poliovirus serotype 1 (23). For polio, the basic reproductive number, R_0, can vary substantially between locations depending on sanitation and hygiene conditions (24). Here we have used an R_0 of 3 for the primary analysis, supported by recent work exploring the parameter space of variable R_0 values in a non-endemic setting in Africa for children under five years of age (20, 25), and explore other R_0 assumptions in a sensitivity analysis (Appendix Table 5). The proportion of children receiving three bOPV doses through RI at 6, 10, and 14 weeks is varied between 25%-100%, and for simplicity is assumed to occur upon entering the model. Children who have not seroconverted following vaccination or did not receive three or more doses of bOPV remain susceptible to infection. The proportion of children vaccinated with one dose of IPV is assumed to be equal to the third dose of bOPV RI coverage, which is in line with WUENIC data (26) (Appendix Figure 2). As of 2020, WHO recommends an additional IPV dose as part of RI (27), however, the number of countries that have introduced IPV2 as of 2023 are limited, therefore, we only consider IPV1 in our model.

We assume a fully mixed population of children under five years of age with no heterogeneity in the probability of a child being vaccinated in an SIA or in transmission of poliovirus. Simulations are run for 50 years before virus introduction, then one infection was introduced into the population at the start of the simulation and further importations were assumed to occur randomly at a rate of two importations per year. Different importation rates are reported in a sensitivity analysis in Appendix Table 6. The model was repeated for 1,000 stochastic simulations and run for five years. All models were run using the R package SimInf (28).

Probability of an outbreak occurring

For each vaccination strategy, the probability of an outbreak was calculated using the proportion of stochastic simulations that resulted in at least one case of paralytic polio (i.e., a polio AFP case) over the entire modelled time horizon. The probability of an outbreak is comparable to maintaining elimination in an infection-free setting such as most African countries. This definition is not directly comparable towards the WHO criteria for elimination status (29), but is useful for understanding outbreak risk. We do not include the specific criteria for elimination status as modelling of the processes that lead towards achieving eradication are beyond the scope of this analysis.

DALYs

DALYs were calculated for each strategy assuming that in LMICs, the average discounted lifetime DALYs associated with one paralytic poliomyelitis case, with no age-weighting is 14 DALYs per paralytic case of polio (30), assuming that one in 200 infections leads to irreversible paralysis and among those paralysed, 5-10% die when respiratory muscles become paralysed (31) and long-term mortality is approximately 20% higher in paralytic polio cases than the general population (32). The proportional contribution of YLD (years lost to disability) and YLL (years of life lost due to premature mortality) assuming 14 DALYs on average per case is 60% YLDs on average per case in addition to 40% YLLs on average per case (33). We assume no international transmission during outbreaks for calculations of DALYs.

Health and economic outcomes

Incremental costs and incremental outcomes (in terms of DALYs and outbreaks averted) were estimated under each pSIA vaccination strategy in comparison to the baseline comparator (RI+oSIAs). We used a 3% discount rate for costs and 0% for health with no age-weighting, with other discounting assumptions explored in Appendix Figure 5. The total cost for each comparator strategy included baseline RI vaccine costs for both bOPV and IPV. We present both a health system (excludes GPEI costs), and GPEI perspective (includes only GPEI costs) for specification of costs, but do not include indirect costs of vaccination, such as opportunity costs of time spent for vaccination.

Vaccine costs

Vaccine costs per dose for bOPV and IPV in Gavi supported countries were obtained from the latest UNICEF update in USD 2023, costing on average $0.18 and $2.00, respectively (34, 35) and administrative costs associated with polio RI were obtained from costs used in previous research (36), Appendix Table 3. All costs have been adjusted to 2023 USD. GPEI estimates OPV wastage ranges from 5-15% in SIAs and wastage is lower in SIAs than in RI (37). Estimates of IPV wastage vary between 5-20% in the literature (38) and country-specific analyses from Nigeria and The Gambia suggest IPV wastage can even be higher in practice, exceeding 20% for IPV wastage in some instances (39, 40). Accordingly, the main analysis assumes an average of 10% wastage for OPV in SIAs, 15% for OPV in RI and 15% for IPV, but further wastage assumptions are explored in a sensitivity analysis (Appendix Figure 6).

Data and analysis on SIAs in Africa

The Polio Information System (POLIS) (41) was used to obtain SIA data for 2013-2022 and further analysis was done to distinguish preventative campaigns from outbreak response campaigns. We assumed that pSIAs included National or Subnational Immunisation Days (NID, SNID) with bOPV (or trivalent OPV (tOPV) pre-2016) that did not occur within 365 days of a WPV1 or VDPV1 detection by AFP surveillance or ES. Any SIA that occurred within this interval was not included in the overall count of pSIAs. Country level historic pSIA number and year of last pSIA were presented alongside WUENIC estimates of Diphtheria Tetanus Toxoid and Pertussis vaccine third dose (DTP3) coverage (42), an indicator of vaccination via RI as the DTP vaccine is administered concurrently with OPV in the routine immunisation series.

SIA costs

The cost per child for both pSIAs and oSIAs was obtained from GPEI data (Appendix Table 7), for which an average across countries within the African Regional Office (AFRO) was used. Historic cost data for oSIAs has been less readily available, therefore, we assume oSIAs cost 2.0 times the cost of a pSIA, as per GPEI estimated costs for 2023. We also explore a range of proportional costs between pSIAs and oSIAs that align with previous assumptions in polio economic modelling (40) (Appendix Figures 7 and 8). Due to the stochasticity of epidemic simulations, there is considerable variability in outcomes for identical assumptions. The number of outbreaks, which affects total estimated costs, is variable and contributes to the variability in expected costs across all strategies (Appendix Figure 3).

Adverse events

The expected risk of adverse events, such as vaccine associated paralytic polio (VAPP) in countries using OPV is 1 case of VAPP per 0.9 million doses of bOPV administered and declines with subsequent doses (43). VAPP rate across settings with and without SIAs has been shown to vary (44), although this variation is not well understood or documented. OPV administration following IPV receipt is associated with a further risk reduction of VAPP (43) and is accounted for in model assumptions (Appendix Table 3). VAPP cases contribute to overall risk and costs for each strategy. A VAPP case was considered equivalent to a case of wild-acquired paralytic polio for calculation of the expected costs of VAPP.

Perspectives

Budget and incremental cost results are analysed from both the GPEI and health system perspectives. The GPEI costs include those associated with SIAs and IPV in RI. Treatment costs associated with paralytic polio (including VAPP) are paid for by the country and are included as health system costs. The probability of an outbreak under each vaccination strategy is analysed from both the global perspective for polio eradication and the country health system perspective.

Ethics

Ethical approval for this project was received from the London School of Hygiene and Tropical Medicine, project ID 15873.

Results

On average across all simulations, the expected number of WPV1 cases over five years is greatest in the baseline strategy (RI+oSIAs) and least in the annual pSIA strategy (RI+oSIAs+annual pSIAs) (Figure 3A). Under the base case assumptions (including R_0 and proportion of zero dose children reached by SIAs) annual pSIAs achieve and maintain >80% probability of no outbreaks when baseline RI coverage is 50% (Figure 3B). The biannual pSIA strategy (RI+oSIAs+biannual pSIAs) achieves >80% probability of no outbreaks when RI is above 65% and the baseline strategy requires ≥75% RI coverage to achieve >80% probability of no outbreaks. The above results are from simulations assuming two importations per year during the five-year period of simulations. The frequency of importations was varied in a sensitivity analysis (Appendix Table 6); when RI was 50% or lower, the increased frequency of importation had a large increase on the probability of outbreaks, but for simulations with an RI ≥75%, the probability of no outbreaks remained above 80%.

Figure 3. Estimated number of paralytic polio cases and probability that no outbreaks occur over the five-year modelled time horizon*, (A) number of expected paralytic polio cases (presenting as a polio AFP case) and (B) probability of no outbreaks occurring across all vaccination strategies. Outbreak probability was based on 1,000 simulations per vaccination strategy. The red dashed line corresponds to 80% probability that no outbreaks occur.*

Expected VAPP cases over five years are greatest in the annual pSIA strategy, corresponding to the strategy with the greatest number of vaccine doses administered, but fewest expected WPV cases over five-years. Estimated costs from both the health system and the GPEI perspectives are shown in Figure 4. From a health system perspective, estimated costs are lowest in the annual pSIA strategy due to fewer polio cases. From the GPEI perspective, estimated costs of the annual pSIA strategy always exceed the cost of the baseline strategy due to the number of preventative campaigns.

Figure 4. Health system and GPEI estimated total costs over five years. *The size of the circle is proportional to the mean number of expected paralytic polio cases across all model simulations. The solid circles correspond to >80% probability the strategy had no outbreaks over a five-year period.*

Incremental costs per DALY averted by both pSIA strategies in comparison to the baseline strategy are shown in Figure 5 with further explanation of the quadrants in a cost-effectiveness plane (Appendix Figure 9). For non-GPEI costs (Figure 5A), when RI coverage exceeds 50%, points for both pSIA strategies are densely clustered in the bottom-right quadrant highlighting approaches with relatively lower costs and more DALYs averted. Assuming herd immunity is calculated by $(1 - 1/R_0)$, when RI coverage exceeds 65%, the point when herd immunity is achieved in this simple homogenously mixed model, the annual pSIA strategy becomes less efficient in averting DALYS. For GPEI costs (Figure 5B), which do not account for treatment or RI bOPV costs, at all levels of RI coverage, the annual pSIA strategy incurs relatively higher costs in comparison to biannual pSIAs, with densely clustered points in top-right quadrant or along the positive y-axis. The cost effectiveness planes are presented in Appendix Figure 5 when a discount rate of 3% has been considered for both health and costs.

Figure 5. Incremental costs per DALY averted. *Incremental costs and DALYs averted under the annual pSIA (RI+oSIAs+annual pSIAs) and biannual pSIA (RI+oSIAs+biannual pSIAs) strategies are compared to the baseline strategy*

(RI+oSIAs) assuming a 3% discount rate for costs and 0% discount rate for health. The points correspond to 1,000 model simulations. Here, it is assumed that the cost per child in an oSIA is two times the cost per child in a pSIA.

Incremental costs per outbreak averted capture the global perspective of polio eradication as a single outbreak under any vaccination strategy has implications for global polio eradication. This analysis has shown a greater number of outbreaks, albeit substantially smaller size, in the annual pSIA strategy in comparison to the baseline strategy when RI coverage is below 45% (under base-case assumptions), but the health system incremental costs are kept down by the small number of polio cases (Figure 6A). From the health system perspective, when RI coverage ranges from 45-70%, the annual pSIA strategy averts many outbreaks in comparison to the baseline strategy, but above 70% RI coverage, the annual pSIA strategy does not avert many outbreaks and is a costly approach. Both pSIA strategies avert few to no outbreaks when RI coverage exceeds 75%. Under the GPEI perspective, the annual and biannual pSIA strategies avert a similar number of outbreaks above 60% RI coverage, but annual pSIAs have higher incremental costs per outbreak averted, corresponding to the greater number of SIAs conducted (Figure 6B).

Figure 6. Incremental costs per outbreak averted. *Incremental costs and outbreak averted under the annual pSIA (RI+oSIAs+annual pSIAs) and biannual pSIA (RI+oSIAs+biannual pSIAs) strategies in comparison to the baseline strategy (RI+oSIAs) assuming a 3% discount rate for costs and 0% discount rate for health. The points correspond to 1,000 model simulations. Here, it is assumed that the cost per child in an oSIA is two times the cost per child in a pSIA. An outbreak is defined as at least one case of paralytic polio. It is important to note that this figure does not suggest that the RI+oSIAs strategy is better performing at low RI coverage levels. Instead, negative (or no) outbreaks averted by both pSIA strategies at low levels of RI coverage correspond to two phenomena: (i) the RI+oSIA strategy has larger explosive outbreaks when RI coverage is low, so the susceptible population is depleted quicker, whilst the pSIA strategies have much smaller, albeit more frequent, outbreaks when RI coverage is low.*

The implications for decision making are outlined in Table 2. Focussing on estimated risk if historic pSIAs have been regularly conducted, when RI coverage falls below 40%, the annual pSIA strategy averts many cases, so removal of pSIAs entirely would create substantial risk. However, pSIAs do not avert many outbreaks. It is important to note that this finding does not suggest that oSIAs are necessarily better performing at these coverage levels. Instead, the baseline strategy instead leads to quicker depletion of susceptibles or, results in more frequent vaccination via outbreak response following *at least one* paralytic case, whereas the pSIA strategies only vaccinate the target population annually or biannually. Countries with 50-90% RI coverage and historic pSIAs have a higher probability of no outbreaks occurring, with the outbreak risk reducing with higher RI. However, the risk of an outbreak is not removed entirely until the probability of no outbreaks reaches 100% (when WPV1 transmission is interrupted globally). All strategies require >95% coverage for 100% probability that no outbreaks occur, however, above 80% RI coverage, outbreak probability is low and, if an outbreak does occur, the expected outbreak size is very small. Figure 1 further summarises country-level historic pSIAs alongside the date since the last pSIA and current estimates of RI coverage. In summary, countries with <60% RI coverage have conducted more recent and frequent pSIAs and countries with >90% RI coverage have, on average, conducted fewer historic pSIAs per year. However, a few countries that fall below 80% RI coverage have not conducted a pSIA in over a decade.

374 ***Table 2. Policy implications of polio vaccination strategies.*** *Implications for adopting each vaccination*
375 *strategy based on a country's RI coverage and historic SIA schedule according to GPEI SIA data (column*
376 *2). Average values across all model simulations are references for DALYs averted and outbreaks*
377 *averted while expected paralytic polio cases are conditional averages amongst simulations that*
378 *resulted in at least one case. The probability of no outbreaks occurring is obtained from the proportion*
379 *of model simulations (out of 1,000 simulations) that resulted in zero paralytic cases and correspond to*
380 *important implications for polio eradication.*

RI coverage	Did country conduct pSIAs in the past?	DALYs averted*?	Outbreaks averted*?	Estimated risk with annual pSIAs	Estimated risk with biannual pSIAs	Estimated risk relying on oSIAs only†	Implications for decision making
				Average number of polio cases if an outbreak occurs‡ (Probability no outbreaks occur)			
35%	✓	✓	X	5 (35%)	894 (3%)	15,753 (0%)	pSIA removal would have high risks and consequences
50%	✓	✓	✓	1 (80%)	4 (33%)	3,549 (1%)	Removal of pSIAs altogether could lead to a high risk of outbreaks in subsequent years
55%	✓	✓	✓	1 (89%)	2 (60%)	617 (3%)	
60%	✓	✓	✓	1 (92%)	1 (76%)	34 (11%)	
65%	✓	✓	✓	1 (94%)	1 (85%)	3 (37%)	
70%	✓	X	✓	1 (96%)	1 (91%)	1 (72%)	
80%	✓	X	✓	1 (97%)	1 (96%)	1 (92%)	Reducing the frequency of pSIAs could still maintain a low risk of large outbreaks
90%	✓	X	✓	1 (99%)	1 (99%)	1 (98%)	
100%	✓	X	X	0 (100%)	0 (100%)	0 (100%)	Even if pSIAs are removed, there is low to no risk of outbreaks

381 * Estimated DALYS and outbreaks averted are obtained from the annual pSIA strategy
382 † Estimated risk is obtained from the oSIA strategy assuming no pSIAs occur
383 ‡ Expected paralytic polio cases were calculated by taking the average number of paralytic polio cases across all stochastic model
384 simulations that had at least one case, so this is the average number of polio cases if an outbreak occurs

Discussion

The key messages of our study are: (i) with higher RI coverage of three doses of bOPV and 1 dose IPV, the probability of outbreaks reduces considerably – under our model assumptions, outbreak size and risk are minimal when RI is above 65%. At lower values of RI, specific vaccination strategies should be considered; (ii) in scenarios where RI is below 50%, annual pSIAs limit outbreak risk and result in high cost, an annual pSIA strategy when RI is 50-80% results in a low probability of outbreaks and continues to be costly, (iii) biannual pSIAs require higher baseline RI coverage (65%) to achieve an equivalent probability of no outbreaks, but the reduction in cost has few negative outcomes; (iv) a strategy with only RI and oSIAs implicitly accepts some level of outbreak risk, but if RI is above 70-80% the risk of outbreaks is considerably less than other settings where RI is below this value.

At low levels (<50%) of RI coverage, the probability of outbreaks is high (99%) following an importation if pSIAs do not occur at any frequency. Further, the incremental costs show a clear benefit of a pSIA strategy, outweighing the increased number of expected VAPP cases and cost of vaccination. Countries such as Madagascar or South Sudan where 55% and 49% of the population under five years of age, respectively, are vaccinated with three or more DTP doses (used to approximate polio RI), have many subpopulations that could benefit from regular pSIAs. Indeed, between 2018-2022 South Sudan has implemented annual pSIAs, and Madagascar has implemented oSIAs in response to cVDPV1. Some countries in Africa have many subpopulations that fall towards the middle or upper range of analysed RI coverage estimates. In both Burkina Faso and Sierra Leone, for example, future SIAs would not seem necessary as routine immunisation coverage of three doses of bOPV and 1 dose IPV exceeds 90% without reliance on historic pSIAs, unless there are subpopulations with substantially lower coverage. The proportion of the population in Malawi that has received three doses of bOPV peaked in 2011, but has been unstable since, falling to 83% in 2016 (26), with no historic reliance on pSIAs. WPV1 was reported in Malawi and local transmission and international spread has since been reported. In our analysis, RI exceeding 80% would be unlikely to result in an outbreak, but we have not included heterogeneity in immunity in the simulations, likely over-estimating the probability of no outbreaks. It may also be that the frequency of WPV1 importation was under-estimated for the Malawi setting, and close monitoring of migration routes from endemic countries remains an important component of preventing polio outbreaks. Whilst WHO now recommends two doses of IPV (IPV2) as part of RI, many countries in Africa have not yet implemented this strategy. As the number of countries adopting this policy decision increases, future studies will be needed to analyse the impact of IPV2.

Our study has health policy implications for decision making on global polio eradication. Despite the high costs, the ability of pSIAs to decrease the probability of an outbreak is an important consideration for polio eradication. Should the GPEI adopt an annual pSIA strategy irrespective of estimated RI and importations? Annual pSIAs that include all children under five years of age in LMICs in Sub-Saharan Africa would consume most of the GPEI annual budget for activities and would be an inefficient use of funds, potentially reducing funds for other activities (surveillance, vaccination against other serotypes). However, prioritising SIAs in countries with low RI and perceived risk of introductions is a necessary compromise to which GPEI already adheres, and here we provide a framework to support decision making. When considering the vaccination strategies based on perceived outbreak risk (as described here) and the fixed budget for these activities, we must balance making the best use of limited resources while limiting WPV1 outbreak risk. The GPEI is reliant on a combination of country donations and philanthropic contributions to support activities, and budget has remained the same or reduced since 2010 and reduced further since the COVID-19 pandemic (45, 46). From the perspective of donors committing to polio eradication, reducing commitment prior to WPV1 interruption is a false saving: for every outbreak experienced, the timeline to WPV1 interruption become longer and the costs of eradication grows (22). Renewed commitment by donors was requested in 2022 (47) in light of the 2022-2026 Strategic Plan and these commitments remain

essential to resource the activities needed to meet the objectives of polio eradication, including interrupting WPV transmission.

Our study has limitations. The main results assume a R_0 of 3 in a homogenous population (both with respect to transmission and population immunity), a frequency of poliovirus introduction of two infections per year and SIAs reaching 25% of children missed by routine vaccination. These assumptions are a necessary simplification of real-world complexity. Several assumptions for R_0, poliovirus introductions, and SIA reach were considered in a univariate sensitivity analysis. Should SIAs reach up to 50% of zero-dose children, the impact of SIAs on reducing outbreak risk is further reduced, consequently for the same costs a better outcome is achieved. Assuming a higher R_0 and increasing the frequency of importations would also increase the outbreak risk. One of the most uncertain inputs of the analysis is importation rate: as poliovirus infection is typically asymptomatic this is not directly observable (although ES has frequently illustrated introductions in the absence of AFP cases (48)), and due to the changing epidemiology of polio globally, the importation rate will vary in time. We have not considered heterogeneity in the population. If there are pockets of the target population with higher rates of transmission and/or lower vaccination coverage, then the probability of an outbreak occurring would be higher. Additional discussion on the model framework is presented in Appendix Section 1, page 5.

Further, the model structure assumes that children are vaccinated when they are born into the population, not accounting for infection prior to vaccination. Because the average age of infection with poliomyelitis occurs after the vaccination schedule of bOPV given at 6, 10 and 14 weeks of age alongside the effect of maternal antibodies, this limitation is unlikely to impact the expected number of AFP cases. However, because the size of the birth cohort vaccinated may be overestimated in the absence of infant mortality assumptions, the costs of RI may be over-estimated here. Additionally, we do not include indirect costs of vaccination, such as opportunity costs of time spent for vaccination, which may result in an underestimation of costs across all strategies. The indirect benefits of these additional interventions (such as productivity increases from averting polio cases) are also not quantified in the costs and benefits of SIAs described here, therefore the deaths and burden averted are polio specific and exclude indirect economic effects, in contrast to some other analyses. Since 2020, pSIAs have been reduced or stopped altogether across most LMICs in Sub-Saharan Africa, meaning 2023 represents the fourth consecutive year of diminished immunity. This analysis does not directly assess the consequences of this diminished immunity but presents baseline research that can be used to inform these future research questions. We do not consider the costs of further delaying the eradication timeline through outbreaks, or the societal implications of outbreaks on polio eradication, both of which may further emphasise the need to implement pSIAs even when the outbreak risks are small. By limiting our analysis to a five-year time horizon, we underestimate the benefits of SIAs (particularly pSIAs) as they will increase the likelihood of eradication, meaning that control efforts after eradication can be scaled back (though not stopped). Further, the pSIA health system costs only consider the geographical remit stated in the model and ignores the potential for further international spread. International spread would be far more likely with larger outbreaks, consequently the health system costs are under-estimated.

In settings that have not recently experienced a WPV1 outbreak, it is challenging to decide between responding to short-term versus long-term risks, especially with a fixed budget. From the global perspective striving to achieve polio eradication, investing in pSIAs results in a greater probability of polio elimination, but still require justification in a pragmatic environment of finite resources. Therefore, future funding provisions and advocacy for the importance of pSIAs rely on research that communicates risk and burden in their absence. Here, we communicate the utility of different vaccination strategies and critically assess the risks associated with adopting different strategies given baseline RI coverage. Decisions made solely based on fixed budget, cost-effectiveness or burden

reduction may not fully capture all consequences or benefits associated with adopting a particular vaccination strategy. Urgently, as importations of WPV remain a threat to the AFRO region, this analysis serves as an invaluable tool to estimate risk and plan vaccination activities across a range of settings.

Authors' contributions

MA and KMOR conceptualised the study. MA curated the data, conducted the modelling analysis, prepared visualisations of results and wrote the original draft. MA, KMOR and KA independently validated the data and results. All authors contributed to reviewing results and editing of the manuscript and have approved the final version. The authors alone are responsible for the views expressed in this article and they do not necessarily present the decisions, policy or views of their affiliated organisations.

Acknowledgements

This project was funded by the Bill and Melinda Gates Foundation (BMGF), OPP1191821. We would like to thank Rachel M. Burke (BMGF), Grace Macklin (WHO), John Edmunds (LSHTM), Anna Vassall (LSHTM), Stephan Widgren (SimInf), and others in the GPEI Subgroup for Analysis and Modelling for their time and feedback over the course of this project.

Declaration of interests

The authors have no conflicts of interest to declare.

Data sharing

Simulation code used in the analysis and sample model outputs can be accessed at: https://github.com/mauzenbergs/polio_econ.

Acronyms

Supplementary Immunisation Activities (SIAs), outbreak response SIAs (oSIAs), planned preventative SIAs (pSIAs), Routine Immunisation (RI), Global Polio Eradication Initiative (GPEI), bOPV (bivalent oral polio vaccine), IPV (inactivated polio vaccine), circulating vaccine derived poliovirus (cVDPV), vaccine associated paralytic polio (VAPP), disability adjusted life years (DALYs), wild poliovirus serotype 1 (WPV1), WHO (World Health Organization), The United Nations Children's Fund (UNICEF), WUENIC (WHO and UNICEF estimates of national immunization coverage), acute flaccid paralysis (AFP), environmental surveillance (ES), African Regional Office (AFRO), Bill and Melinda Gates Foundation (BMGF), low- or middle-income country (LMIC), London School of Hygiene and Tropical Medicine (LSHTM), standard operating procedures (SOP).

References

1. Etsano A, Gunnala R, Shuaib F, Damisa E, Mkanda P, Ticha JM, et al. Progress toward poliomyelitis eradication—Nigeria, January 2014–July 2015. Morbidity and Mortality Weekly Report. 2015;64(32):878.
2. Malawi Ministry of Health, Global Polio Eradication Initiative, Davlantes E. Notes from the Field: Initial Outbreak Response Activity Following Wild Poliovirus Type 1 Detection—Malawi, February 2022. Morbidity and Mortality Weekly Report. 2022;71(23):776-7.
3. Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O'Leary A, et al. Progress Toward Polio Eradication - Worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650-5.
4. McCarthy K, Howard W, Yousif M, Moonsamy S, Suchard M. The show is not over–wild-type polio in Malawi is a wake up call and an opportunity for elimination efforts. International Journal of Infectious Diseases. 2022.
5. O'Reilly KM, Lamoureux C, Molodecky NA, Lyons H, Grassly NC, Tallis G. An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. BMC Infect Dis. 2017;17(1):367.
6. Stephen B Kennedy GRM, Gloria Mason Ross. Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Global Health. 2023.
7. Franco-Paredes C, Rodriguez-Morales AJ, Henao-Martínez AF, Carrasco P, Tuells J. The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era. The Lancet Infectious Diseases. 2022;22(10):1412-4.
8. Global Polio Eradication Initiative. Polio endgame strategy 2019-2023: eradication, integration, certification and containment. World Health Organization; 2019.
9. Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022.
10. Global Polio Eradication Initiative. GPEI Multi-year Budget 2019-2023: Enabling GPEI to Interrupt Poliovirus Transmission & Achieve Certification.
11. Thompson KM, Kalkowska DA. An updated economic analysis of the Global Polio Eradication Initiative. Risk Analysis. 2021;41(2):393-406.
12. Thompson KM, Tebbens RJD. Eradication versus control for poliomyelitis: an economic analysis. The Lancet. 2007;369(9570):1363-71.
13. Zimmermann M, Hagedorn B, Lyons H. Projection of Costs of Polio Eradication Compared to Permanent Control. The Journal of Infectious Diseases. 2019;221(4):561-5.
14. Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661-86.
15. Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective. Vaccine. 2003;21(7):702-5.
16. Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J Vaccines Vaccin. 2016;7(5).
17. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling Strategies to Increase Population Immunity and Prevent Poliovirus Transmission in 2 High-Risk Areas in Northern India. The Journal of Infectious Diseases. 2014;210(suppl_1):S398-S411.
18. Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus event or outbreak 2022 [Version 4:[Available from: https://polioeradication.org/wp-content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220417_OBR_SOP_final_pre_pub_website.pdf.
19. Blake IM, Chenoweth P, Okayasu H, Donnelly CA, Aylward RB, Grassly NC. Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. Emerg Infect Dis. 2016;22(3):449-56.
20. Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, et al. The role of older children and adults in wild poliovirus transmission. Proceedings of the National Academy of Sciences. 2014;111(29):10604-9.
21. Voorman A, Lyons HM. Measuring polio immunity to plan immunization activities. Vaccine. 2016;34(48):5946-52.

576 22. World Health Organization, Global Polio Eradication Initiative. Polio eradication strategy 2022–
577 2026: delivering on a promise. 2021.
578 23. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis
579 deconstructed. American journal of epidemiology. 2010;172(11):1213-29.
580 24. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Polio Vaccine Viruses:
581 Implications for the Global Poliomyelitis Eradication Initiative. American Journal of Epidemiology.
582 1999;150(10):1001-21.
583 25. McCarthy KA, Chabot-Couture G, Shuaib F. A spatial model of Wild Poliovirus Type 1 in Kano State,
584 Nigeria: calibration and assessment of elimination probability. BMC Infectious Diseases. 2016;16(1):521.
585 26. World Health Organization. Poliomyelitis vaccination coverage.
586 27. World Health Organization. Weekly Epidemiological Record, 2020, vol. 95, 22 [full issue].
587 2020;95(22):241-56.
588 28. Widgren S, Bauer P, Eriksson R, Engblom S. SimInf: An R package for data-driven stochastic disease
589 spread simulations. arXiv preprint arXiv:160501421. 2016.
590 29. Dowdle WR. The principles of disease elimination and eradication. Bulletin of the World Health
591 Organization. 1998;76(Suppl 2):22.
592 30. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, et al. Economic
593 analysis of the global polio eradication initiative. Vaccine. 2010;29(2):334-43.
594 31. World Health Organization. Poliomyelitis [Available from: https://www.who.int/news-room/fact-
595 sheets/detail/poliomyelitis.
596 32. Nielsen NM, Rostgaard K, Juel K, Askgaard D, Aaby P. Long-term mortality after poliomyelitis.
597 Epidemiology. 2003:355-60.
598 33. World Health Organization. The global burden of disease: 2004 update: World Health
599 Organization; 2008.
600 34. UNICEF. Inactivated Polio Vaccine (IPV) price data [Available from:
601 https://www.unicef.org/supply/media/16266/file/IPV-vaccine-prices-14032023.pdf.
602 35. UNICEF. oral polio vaccine price data 2022 [Available from:
603 https://www.unicef.org/supply/media/12671/file/oral-polio-vaccine-price-data-08062022.pdf.
604 36. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy
605 options: 2019–2029. Risk Analysis. 2021;41(2):364-75.
606 37. UNICEF. Guidance Note on Cold Chain Logistics and Vaccine Management During Polio
607 Supplementary Immunization Activities. UNICEF, New York, NY; 2015.
608 38. Mvundura M, Hsu J-S, Frivold C, Kristensen D, Boyle S, Zehrung D, et al. Evaluating the cost per
609 child vaccinated with full versus fractional-dose inactivated poliovirus vaccine. Vaccine: X. 2019;2:100032.
610 39. Wallace AS, Willis F, Nwaze E, Dieng B, Sipilanyambe N, Daniels D, et al. Vaccine wastage in Nigeria:
611 An assessment of wastage rates and related vaccinator knowledge, attitudes and practices. Vaccine.
612 2017;35(48 Pt B):6751-8.
613 40. Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk
614 Analysis. 2021;41(2):349-63.
615 41. Global Polio Eradication Initiative. Polio Information System. 2023.
616 42. World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage.
617 43. Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes
618 and epidemiology of poliomyelitis in the United States. Jama. 2004;292(14):1696-701.
619 44. Tebbens RJD, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease
620 due to wild or vaccine-derived poliovirus after eradication. Risk Analysis. 2006;26(6):1471-505.
621 45. OECD. The 0.7% ODA/GNI target - a history [Available from: https://www.oecd.org/dac/financing-
622 sustainable-development/development-finance-standards/the07odagnitarget-ahistory.htm.
623 46. Philip Loft PB. The 0.7% aid target. 2022.
624 47. Global Polio Eradication Initiative. GPEI calls for renewed commitments to achieve promise of a
625 polio-free world 2022 [Available from: https://polioeradication.org/news-post/global-polio-eradication-
626 initiative-calls-for-renewed-commitments-to-achieve-promise-of-a-polio-free-world/.
627 48. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al. Environmental
628 surveillance for polioviruses in the Global Polio Eradication Initiative. The Journal of infectious diseases.
629 2014;210(suppl_1):S294-S303.

A



B

Country	DTP3 coverage 2021	Year of last pSIA
RI coverage <50%		
CAR	42%	2021
Somalia	42%	2021
Guinea	47%	2021
South Sudan	49%	2021
>50% RI coverage <80%		
Madagascar	55%	2019
Nigeria	56%	2021
Chad	58%	2021
Mozambique	61%	2011
DRC	65%	2021
Ethiopia	65%	2021
Cameroon	69%	2021
Côte d'Ivoire	76%	2018
Benin	76%	2018
Mali	77%	2019
>80% RI coverage <90%		
Gambia	82%	2014
Niger	82%	2019
Togo	83%	2014
Sudan	84%	2019
Senegal	85%	2016
South Africa	86%	2010
Zimbabwe	86%	2007
>90% RI coverage		
Burkina Faso	91%	2016
Kenya	91%	2019
Uganda	91%	2019
Zambia	91%	2009
Sierra Leone	92%	2019
Malawi	93%	2010
Burundi	94%	2011
Botswana	95%	2004
Ghana	98%	2015

Figure 1.


Opportunities for vaccination
RI
pSIAs
oSIAs
Vaccination increases population immunity
Increasing RI coverage or the frequency of SIAs increases the number of vaccine doses administered
Number of paralytic poliomyelitis cases
Probability of NO outbreaks
Number of VAPP cases
Effect on DALYs from paralytic poliomyelitis cases
Effect on DALYs from outbreaks
Effect on DALYs from VAPP cases
Costs from paralytic poliomyelitis cases
Costs from outbreaks
Costs from VAPP cases

Figure 2.


A
Expected paralytic polio cases over 5 years
Number of expected AFP cases
20,000
15,000
10,000
5,000
0
40
60
80
100
RI coverage (%)
B
Probability that no outbreaks occur
Probability that no outbreaks occur based on 1,000 simulations per strategy
100
90
80
70
60
50
40
30
20
10
40
60
80
100
RI coverage (%)
Vaccination strategy
RI + oSIAs
RI + oSIAs + annual pSIAs
RI + oSIAs + biannual pSIAs

Figure 3.

Total costs over 5 years

Size of the circles is proportion to the number of expected AFP cases
Solid points indicate >80% probability of no outbreak



Figure 4.



Figure 5.

Baseline comparator strategy is RI + oSIAs
3% discounting for costs, 0% discounting for health



Figure 6.

Baseline comparator strategy is RI + oSIAs
3% discounting for costs, 0% discounting for health

Appendix

Table of Contents

Section 1: Model structure, parameters and limitations

i. *Appendix Figure 1 – SIR model structure*
ii. *Appendix Table 1 - Model compartments and transitions*

Section 2: Model parameters and cost assumptions

i. *Appendix Figure 2 – WUENIC coverage estimates supporting vaccination coverage assumptions*
ii. *Appendix Table 2 – Model parameters*
iii. *Appendix Table 3 – Cost inputs*

Section 3: Stochastic simulations result in variable outcomes across strategies

i. *Appendix Figure 1 – Variable number of outbreaks across strategies*
ii.
iii. *Appendix Figure – Average number of expected AFP cases, expected VAPP cases and DALYS across all vaccination strategies*

Section 4: Sensitivity analyses

i. *Appendix Figure 5 – Sensitivity analysis: 3% discounting for health*
ii. *Appendix Figure 6 – Sensitivity analysis: budget impact under different wastage assumptions*
iii. *Appendix Figure 7 – Sensitivity analysis: incremental costs and DALYs averted under different oSIA cost assumptions*
iv. *Appendix Figure 8 – Sensitivity analysis: incremental costs and outbreaks averted under different oSIA cost assumptions*
v. *Appendix Table 4 – Sensitivity analysis: model outputs under different assumptions about the proportion of children reached by SIAs*
vi. *Appendix Table 5 – Sensitivity analysis: model outputs under different assumptions about* R_0
vii. *Appendix Table 6—Sensitivity analysis: model outputs under different assumptions about importation rate*

Section 5: Supporting information

i. *Appendix Table 7—Proportional costs between pSIAs and oSIAs*
ii. *Appendix Figure 9 – Cost-effectiveness quadrants for interpretation of incremental results*

Section 1: Model structure, parameters and limitations

Model structure

A stochastic non-linear mathematical model was used to simulate polio transmission dynamics, whereby infectious individuals develop either asymptomatic (I, or infectious, compartment in Appendix Figure 2), or symptomatic infection (C, or case, compartment), both of which are assumed to be infectious. Both infections and cases recover to the Rn compartment. In the model, children are either susceptible (S0 compartment), fully vaccinated and protected from poliovirus infection (Rv compartment) or have received an incomplete vaccination series (less than 3 bOPV doses + 1 IPV dose, modelled separately). Children who were not vaccinated via RI, can receive additional doses of bOPV vaccine through either pSIAs or oSIAs. Each subsequent dose of vaccine corresponds additional protection and an opportunity for a child to seroconvert and be considered fully protected from poliovirus infection (corresponding to each of the Sn tiers).

The left side of Appendix Figure 1 corresponds to children missed by RI who have an opportunity for additional bOPV doses via SIAs. Progression through the model to different Sn compartments happens only at the time of an SIA.

The right side of Appendix Figure 1 corresponds to RI and happens daily, when life births enter the population. Children vaccinated via RI are assumed to receive a sequential schedule of both bOPV and IPV, whereby they are assumed to seroconvert and be protected from poliovirus (transitioning to Rv compartment). Only children previously vaccinated via RI are eligible for vaccination with IPV and IPV is provided alongside the third dose of bOPV via RI in most African countries.

In the main analysis, we assume that IPV = bOPV coverage, but if IPV<OPV, children who were vaccinated with bOPV doses via RI, but did not complete their vaccination series and receive IPV, could be eligible for additional bOPV doses via SIAs, representing compartments in the grey shaded box.

To guide understanding of the model diagram, the compartments correspond to the following:

- S0 = susceptible to poliovirus, no vaccine received
- I = infectious, but asymptomatic
- C = infectious and polio (AFP) case
- Rn = recovery via natural infection
- S_n = susceptible to poliovirus infection, but have received n bOPV doses via SIAs
- $RI_{3bOPV + IPV}$ = vaccinated with 3 bOPV doses + IPV at birth via RI
- $S3_{RI}$ = vaccinated with bOPV, but missed IPV dose



Appendix Figure 1. Model structure of the extended SIR model. Births enter the population either via the S0 compartment or the $S3_{ri}$ compartment, assuming vaccination with three bOPV doses occurs via RI at the time of birth. Children can exit the population from any compartment via death. Children missed by RI at birth remain in the S0 compartment, with potential for vaccination with one dose of bOPV via pSIA or oSIA. Following vaccination during an SIA, a child can then progress to the S1 compartment. Each of the SIA tiers (S1, S2, S3, S4), correspond to the number of bOPV doses received via an SIA and allow for potential seroconversion and transition to the Rv compartment according to assumed bOPV vaccine efficacy at any one of these tiers. Children who do not seroconvert following bOPV during an SIA progress to the next vaccination tier and await subsequent SIA vaccination. Each of the SIA tiers remain susceptible to infection. In this model we assume that bOPV coverage = IPV coverage, however, the model is set up such that if these coverage values are not equal, if a child receives three bOPV doses but no IPV dose, they remain eligible for a 4th bOPV dose via SIAs (grey shaded box).

Model compartments and transitions

A review of the immunogenicity of vaccination schedules with both IPV and three doses of bOPV indicate high rates of seroconversion alongside some geographical variability [1] and sustained protection against paralytic poliomyelitis [2]. Accordingly, we assume seroconversion and transition to the Rv compartment is 100% for children who received three doses of bOPV and one dose of IPV and no waning of protection. The assumptions described here about vaccination activities provide a 'steady state' immunity profile which we use to explore the effects of polio introductions. We assume that once five years of age is reached, children are no longer relevant to poliovirus transmission, due to the high likelihood of immunity against infection due to vaccination.

Appendix Table 1. Model compartments and corresponding explanation of compartmental transitions and assumptions

Compartment	Assumption
S0	Individuals in this compartment have not been vaccinated, i.e., zero doses received of both bOPV and IPV. The proportion of unvaccinated individuals born into this compartment depends on assumed RI coverage. From S0, individuals exposed to 1 dose of bOPV via an SIA progress to S1. Individuals who stay in S0 remain susceptible to infection.
S1	Individuals in this compartment have received 1 dose of bOPV via an SIA. Individuals in S1 did not receive 3 doses of bOPV via RI at birth, therefore, their only opportunity for vaccination was via an SIA. From S1, a certain proportion will seroconvert after 1 dose and transition to Rv, according to bOPV vaccine efficacy (see parameter ϕ below). While those that did not seroconvert stay in S1 and remain susceptible to infection or able to be vaccinated in a subsequent SIA.
S2	Individuals in this compartment have received 2 doses of bOPV via an SIA. From S2, a certain proportion will seroconvert after 2 doses and transition to Rv, according to bOPV vaccine efficacy (see parameter ϕ below). While those that did not seroconvert stay in S2 and remain susceptible to infection or able to be vaccinated in a subsequent SIA.
$S3_{sia}$	Individuals in this compartment have received 3 doses of bOPV via an SIA. From $S3_{sia}$, a certain proportion will seroconvert after 3 doses and transition to Rv, according to bOPV vaccine efficacy (see parameter ϕ below). While those that did not seroconvert stay in $S3_{sia}$ and remain susceptible to infection or able to be vaccinated in a subsequent SIA.
S4	Individuals in this compartment have received 4 doses of bOPV and therefore, 100% are assumed to seroconvert and transition to Rv.
$RI_{3bOPV + IPV}$	Assuming that bOPV coverage = IPV coverage. Children in this compartment are vaccinated via RI with a sequential schedule of OPV/OPV/IPV/OPV. It is assumed after 3 doses of bOPV and 1 dose IPV 100% of children seroconvert and transition to the Rv compartment and are also protected from paralysis.
$S3_{ri}$	Individuals in this compartment received 3 doses of bOPV at birth via RI. From $S3_{ri}$, a certain proportion will seroconvert after 3 doses and transition to Rv, according to bOPV vaccine efficacy (see parameter ϕ below). If IPV coverage ≠ bOPV coverage, those who did not seroconvert after 3 doses of bOPV are eligible for vaccination with 1 dose of IPV, depending on assumed IPV coverage (see ω parameter below), or receive a 4th bOPV dose from an SIA. Of those vaccinated with IPV, 100% are assumed to seroconvert and transition to Rv
I	Individuals in this compartment are infectious, but asymptomatic. They can spread infection to others but are not a paralytic case of polio. Importations of infection who enter the population enter via this compartment.

C	Individuals in this compartment are a paralytic case of polio. They can spread infection to others and trigger an outbreak response campaign in the RI+oSIA strategy.
Rn	Individuals in this compartment have recovered from natural infection and are assumed immune to subsequent infection.
Rv	Individuals in this compartment have received sufficient vaccination to result in seroconversion and are assumed immune to subsequent infection.

Model framework

It is important to discuss the model framework used in this analysis and associated pros and cons of the simplistic model structure and assumptions. Model simplicity allows for easy interpretation and is applicable to a range of settings. Here, we model a hypothetical population size for a LMIC in sub-Saharan Africa using certain fixed parameters, but the simple model structure can be easily adapted to fit specific countries, or even subnational populations. The model compartments and transitions are easy to understand by a wide range of audiences, not just mathematical modellers and the SimInf package allows for easy adaptation of scheduled vaccination activities to local contexts. The SimInf package also does not require extensive coding experience of complex transmission models and differential equations and the available model code associated with this analysis is easily reproducible. To reach a wide audience of stakeholders involved in global polio eradication, the simplicity of model structure was an important consideration for this analysis.

The simplicity of the model does give rise to several limitations. In this model, we assume homogenous mixing, assume that the same polio programme has been in place for 50 years prior to model initiation, assume SIAs reach 25% of children unvaccinated by RI, assume a single value for R_0 and other model parameters with no uncertainty. Of particularly importance is heterogeneity in the population structure. If there are pockets with higher rates of transmission or lower vaccination coverage (or both) then this would increase the likelihood of outbreaks and thus decrease the likelihood that eradication will be achieved. Sensitivity analyses in Appendix Section 4 further explore varying assumptions about SIA target population, importation rate and R_0. In summary, under different assumptions, model outputs across vaccination strategies are only affected when RI coverage is very low and therefore, support the assumptions used in the main analysis.

Section 2: Model parameters and cost assumptions

IPV and OPV coverage estimates

This WEUNIC data shows the relationship between IPV and OPV3 coverage (three doses of bOPV vaccine) for twenty-five countries in sub-Saharan Africa. IPV was introduced later in time in all countries, and although at the time of introduction IPV coverage was lower than OPV3 coverage in most countries, in 2021, IPV and OPV3 coverage was roughly equal across all countries. This data supports the model assumption that IPV coverage = OPV3 coverage, or all children that receive a third dose of bOPV, also received IPV via RI.

Appendix Figure 2. WUENIC coverage estimates 2000-2021 for OPV3 and IPV1 across twenty-five low-and-middle income Sub-Saharan African countries. The strong correlation between OPV3 and IPV1 coverage estimates in 2020 and 2021 (when scale-up of IPV implementation was reached) support model assumptions that OPV coverage is equal to IPV coverage.

Model parameters and assumptions

Appendix Table 2. Table of model parameters and corresponding values and assumptions

Parameter	Value	Assumption
γ	1/8	γ = recovery rate – the infectious period for polio is between 7-10 days before AND after symptoms. Here, we took the average, 8 days that an individual can remain in the I or C compartment, before transitioning to R_n
R_o	3	Basic reproductive number
β	0.375	Calculated knowing R0 is 3, and recovery rate is 1/8
ρ	1/200	Case to infection ratio for WPV
κ	Varied between 0.25 – 1.0	Proportion that received 3 doses of bOPV via RI
ζ	0.25	Proportion of the target population reached by the SIA, those missed by the campaign are represented by 1- ζ
ω	Varied between 0.25 – 1.0	Proportion exposed to IPV vaccination
ϕ	$1 - ((1 - 0.5)^{doses})$	Vaccine effectiveness of bOPV for protection against serotype 1, i.e., the proportion of the population that seroconvert and transition to Rv assuming vaccine efficacy (VE) is 50%
μ	$5*10^{-4}$ * population	Birth rate = death rate 4,000 live births per day in a country of 8 million is the average number of live births across African countries
Herd immunity	$1-1/R_0$	Using an R_0=3, the herd immunity threshold would be assumed to be reached at 66.67% RI coverage

Cost assumptions

We assume costs of SIAs are the same across the entire modelled time horizon. Costs associated with vaccine doses and the number of children vaccinated during an SIA are estimated using the entire target population of eight million children under five years of age, even though in practice, the true proportion of children reached during SIAs is often much lower due to operational challenges and other logistical shortcomings [3]. As model outputs captured the variability across all stochastic simulations, costs for each individual simulation were calculated across all strategies. The average expected costs for each strategy were then obtained by taking the mean cost across all simulations for each corresponding strategy. The GPEI costs include those associated with SIAs and IPV in RI. Treatment costs associated with paralytic polio (including VAPP) are paid for by the country and includes as health care system costs.; specific equations used in the costing estimates can be found below in Appendix Table 3.

Literature has shown that costs associated with RI administration can vary across RI coverage for different antigens [4, 5], but usually the threshold cut-off is below and above 80% RI coverage and explicit evidence of this differential for polio is not well documented. Accordingly, we use one value for costs associated with RI administration for polio as documented by Kalkowska et al.

Appendix Table 3. Table of cost inputs and corresponding values and assumptions

Item	Value (USD$2023)	Assumption / reference
bOPV dose	$0.18	Average cost for a GAVI country [5], price per dose in a 10-dose vile
IPV dose	$2.00	For a GAVI country 10-dose vile and translated into USD$2023 [6]
RI OPV admin	$1.06*3 doses	Costs associated with administration, procurement and storage of OPV for use in RI. 2019 costs were obtained from appendix Table A1 [7]. We assume costs and wastage are based on the size of the entire birth cohort.
RI IPV admin	$2.00	Costs associated with administration, procurement and storage of IPV for use in RI. 2019 costs were obtained from appendix Table A1 [7]. We assume costs and wastage are based on the size of the entire birth cohort.
pSIA	$0.50/child	Includes operational costs, social mobilisation and administration. We assume that SIAs are planned to reach 100% of the population and costed accordingly but the actual population vaccinated is 25% due to operational challenges. Costs are obtained from GPEI
oSIA	$1.0/child Range: $0.50 – $1.50/child	Includes costs associated with emergency response to an outbreak. We assume that SIAs are planned to reach 100% of the population and costed accordingly but the actual population vaccinated is 25% due to operational challenges. Costs are estimated based on GPEI costs for pSIAs
VAPP rate	Dependent on dose and vaccination schedule	1st dose: 0.9 VAPP cases/1 million bOPV doses administered, a 6.6-fold greater risk than following subsequent doses [8] The risk of VAPP following OPV vaccination is reduced if IPV has been received. We assume no risk of VAPP associated with IPV vaccination and a 53% reduction in

		VAPP cases following bOPV if IPV has already been received
DALY	14/paralytic case	Assume AFP case = VAPP case
Paralytic case	$700/case	Assume AFP case = VAPP case, cost is for a low-income country [4]
bOPV wastage RI	Range 10-20%	Range of estimated wastage of bOPV in RI [9, 10]
bOPV wastage SIA	Range 5-15%	Range of estimated wastage of bOPV in both pSIAs and oSIAs [9, 10]
IPV wastage RI	Range 5-20%	Range of estimated wastage of IPV in routine settings. Range varies based on vial size and setting [9, 10]
Health care system & non-GPEI costs		Treatment costs (red) + RI OPV costs (blue) Cost per AFP case + Cost per VAPP case + (Births * OPV wastage for RI * Cost per dose of bOPV * total doses received per child * RI costs for OPV administration)
GPEI costs		SIA costs (green) + RI IPV costs (orange) (SIA target population * OPV wastage for SIAs * Cost per dose of bOPV * Number of SIAs * SIA cost per child) + (Births * IPV wastage for RI * Cost per dose of IPV * RI costs for IPV administration)

Section 3: Stochastic simulations result in variable outcomes across strategies

Variable number of outbreaks across all strategies



Appendix Figure 1. Number of outbreaks in each individual model simulation for each vaccination strategy, among simulations with ≥1 paralytic polio case. The low number of outbreaks at RI coverage levels >70% correspond to a lower probability of an outbreak, which was lowest in the annual pSIA strategy.

The stochasticity of epidemics means that there is considerable variability in outcome for identical assumptions focussing on simulations that had ≥1 paralytic polio case (Appendix Figure 1). We define an outbreak as at least one case of paralytic poliomyelitis, which we assume would present as acute flaccid paralysis (AFP). To count the total number of outbreaks, all cases that occurred within 90 days of the first case were considered part of the same outbreak. Cases that occurred in subsequent intervals of 90 days were considered part of different independent outbreaks. Even though some cases that are allocated to different outbreaks may in fact be linked or a part of the same outbreak, the 90-day threshold aligned with the schedule of oSIAs and was used as a consistent unit to count outbreaks across strategies. This method of counting outbreaks may incorrectly attribute linked cases from the same outbreak as independent outbreaks but was taken to reduce model complexity. As standard operating procedures for polio outbreaks recommend an oSIA in affected areas within 90-days of the first case, if an outbreak is not stopped or subsequent cases arise later, this would trigger a subsequent oSIA, a chronology which is accurately accounted for in this analysis. In the absence of having uniquely identifiable outbreaks within the model, simplifying the outbreak count by using a 90-day cut-off is a limitation that may over-estimate the total number of outbreaks, however, the counting methodology is consistent across all evaluated strategies.

Trends in VAPP and DALYs

Expected VAPP cases over the same interval are greatest in the annual pSIA strategy, corresponding to the strategy with the greatest number of vaccine doses administered (Appendix Figure 4). The annual pSIA strategy administers the greatest number of vaccine doses and is the strategy that results in the fewest expected WPV cases over five-years (main text figure 2A). At RI coverage levels below 70%, DALYs incurred are greatest in the RI+oSIA strategy, the strategy with the greatest number of expected AFP cases. However, at RI coverage levels >70%, the average number of VAPP cases exceeds the number of WPV1 cases in all pSIA strategies, which drives these two strategies to have a greater number of estimated DALYs lost than the RI strategy alone. Expected DALYs in the annual pSIA strategy are greatest when RI coverage exceeds 70% because the number of pSIAs remains constant over time, resulting in more VAPP cases and consequently, a greater number of DALYs incurred. In contrast, above 70% RI coverage, the RI+oSIA strategy has fewer WPV1 cases and no or fewer oSIAs, resulting in fewer VAPP cases and therefore fewer expected DALYs incurred. When more optimistic assumptions about SIA coverage were made, results followed similar trends and the only substantial difference between expected AFP cases and outbreak probability was at RI coverage levels below 35% (Appendix Table 4).



Appendix Figure 4. Average number of expected VAPP cases and DALYs per capita over 5 years amongst model simulations that reported at least one outbreak. The increase in VAPP cases is related to the increase in vaccine doses administered. In figure 4A, the mean number of VAPP cases were obtained from all model simulations for each vaccination strategy. In figures 4B and 4C, DALYs include DALYs associated with both paralytic polio cases and DALYS and are split by two thresholds of RI coverage, above and below 70%, in order to illustrate the reversal in strategy ranking for DALYs at low and high levels of RI coverage.

Section 4: Sensitivity analyses

Sensitivity analysis—discounting for health



Appendix Figure 5. Incremental costs per DALY averted under the annual pSIA and biannual pSIA strategies in comparison to the RI+oSIA strategy assuming a 3% discount rate for costs and 3% discount rate for health. Incremental costs are split between health system/non-GPEI perspective and GPEI perspective and the plots are facetted by RI coverage level. The points correspond to 1,000 stochastic model simulations.

Sensitivity analysis – different assumptions about vaccine wastage



Appendix Figure 6. Total costs over five years under different wastage assumptions. The top plots represent conservative estimates of wastage using the lowest limit of the range of published wastage rates for both OPV and IPV vaccination via RI and SIAs while the bottom plots use the highest limit of the range of published wastage rates.

Sensitivity analysis – different proportional costs between pSIAs and oSIAs



Appendix Figure 7. Sensitivity analysis exploring incremental costs per DALY averted under variable assumptions about oSIA costs. The different colours represent different proportional differences between annual pSIAs and oSIAs. For example, "Annual pSIAs if oSIA:pSIA costs are 3:1" presents the incremental costs and DALYs averted by annual pSIAs if oSIAs cost three times as much as pSIAs. The points correspond to 1,000 stochastic model simulations.

A sensitivity analysis explored incremental costs under variable assumptions about the proportional difference in costs between oSIAs and annual pSIAs. The main analysis assumed the cost per child for an oSIA was twice the cost per child for a pSIA, but available outbreak response cost data suggests a range across African countries. In the sensitivity analysis, two alternative cost assumptions were explored: (I) the cost per child in an oSIA equalled the cost per child in a pSIA (1:1) and (II) the cost per child of an oSIA was three times the cost per child in a pSIA (3:1). The RI+oSIA strategy is always the baseline comparator, but here, the total costs of the baseline comparator change: (blue) baseline comparator is oSIAs if the proportional costs are 1:1 with pSIAs, (pink) baseline comparator is oSIAs if the proportional costs are 2:1 (as in the main analysis), and (green) baseline comparator is oSIAs if the proportional costs are 3:1 with pSIAs. This sensitivity analysis answers the question, under what cost assumptions are annual pSIAs more cost-effective than oSIAs? Appendix Figure 7 shows the incremental costs per DALY averted across all oSIA assumptions and Appendix Figure 8 shows incremental costs per outbreak averted from the GPEI perspective as GPEI costs include SIA costs. When RI coverage exceeds the herd immunity threshold, the number of outbreaks, and consequently, the number of oSIAs required substantially decreases causing the GPEI incremental costs to be aligned across all oSIA cost assumptions. Using the equation for Incremental Cost Effectiveness Ratios (ICER), we can comment on the correlation between different proportional costs and the change of direction in incremental costs:

$$ICER = \frac{(costs\ of\ pSIA\ strategy - costs\ of\ RI + oSIA\ strategy)}{(DALYs\ or\ outbreaks\ averted\ by\ pSIA\ strategy)}$$

If we focus on DALYs, when RI coverage is below 60%, annual pSIAs are the least cost-effective when proportional costs between pSIAs and oSIAs are 1:1 because under this assumption, the RI+oSIA strategy is less costly, so the numerator increases. Or, the annual pSIA strategy costs much more than the oSIA per DALY averted. Conversely, when proportional costs between pSIAs and oSIAs are 3:1, the numerator shrinks, so the difference in costs between annual pSIAs and oSIAs is less per DALY averted. When RI coverage increases above 60%, few to no DALYs are averted by annual pSIAs in comparison to oSIAs, but costs remain high as the annual pSIA strategy maintains annual campaigns regardless of outbreak number.



Appendix Figure 8. Sensitivity analysis exploring incremental costs per outbreak averted under variable assumptions about oSIA costs. The different colours represent different proportional differences between pSIAs and oSIAs. For example, "Annual pSIAs if oSIA:pSIA costs are 3:1" presents the incremental costs and outbreaks averted by annual pSIAs if oSIAs cost three times as much as pSIAs. The points correspond to 1,000 stochastic model simulations.

Focussing on outbreaks, the annual pSIA strategy does not avert any outbreaks when RI coverage is below 40%, a phenomenon described in the main text for figure 6. At these RI coverage levels, the annual pSIA strategy costs more to avert no outbreaks, and if annual pSIAs are the same cost as oSIAs, the incremental costs are even high per outbreak (not) averted. When RI coverage exceeds 40%, the annual pSIA strategy averts outbreaks but is more costly than the RI+oSIA strategy. Specifically, if the proportional costs are 1:1, the incremental costs of annual pSIAs per outbreak averted are greatest and least when proportional costs between pSIAs and oSIAs are 3:1.

Sensitivity analysis – different assumptions about proportion of children reached by SIAs

The true effectiveness of SIAs (defined as the product of coverage and vaccine efficacy) remains uncertain in practice; although vaccine efficacy is well described in clinical trials, it is known to vary by population, and the population coverage achieved is uncertain resulting in variable effectiveness. For example, mathematical modelling demonstrates a dramatic range of SIA effectiveness estimates in Tajikistan versus the Republic of Congo: in Tajikistan, SIA effectiveness in response to a localised outbreak was estimated to be 69% (95% CI 55-80%) while in the Republic of Congo, SIA effectiveness was estimated to be 0.4% (95% CI 0.0-14.0%) per SIA [11]. In this analysis we define the SIA target population as children missed by RI. As research suggests that SIA effectiveness is highly variable in different locations, this model assessed outcomes under the assumption that all pSIAs and oSIAs reach 25% of the population missed by RI and bOPV vaccine efficacy is 50%. In the sensitivity analysis below (Appendix Table 4), we explore the average number of expected AFP cases over five years and the probability of an outbreak if SIAs reached 50% of the target population, or 50% of children under five years of age who were missed by RI.

*Appendix Table 4. Expected average number of AFP cases and expected probability of an outbreak if each SIA were expected to reach 50% of the target population instead of the 25% assumption in the main analysis. Assumptions about vaccine efficacy are the same across all models. Expected AFP cases were calculated by taking the average number of AFP cases across all stochastic model simulations that had **at least one AFP case.***

RI coverage	SIA strategy	If SIAs vaccinate 25% of the target population		If SIAs vaccinate 50% of the target population	
		Average number of expected AFP cases over 5 years	Expected probability of an outbreak	Average number of expected AFP cases over 5 years	Expected probability of an outbreak
25%	RI + oSIA + annual pSIA	176	88%	1	16%
35%	RI + oSIA + annual pSIA	5	65%	1	9%
50%	RI + oSIA + annual pSIA	1	20%	1	6%
75%	RI + oSIA + annual pSIA	1	4%	1	2%
25%	RI + oSIA + biannual pSIA	5,564	99%	15	83%
35%	RI + oSIA + biannual pSIA	894	97%	3	56%
50%	RI + oSIA + biannual pSIA	4	67%	1	17%
75%	RI + oSIA + biannual pSIA	1	6%	1	6%
25%	RI + oSIA	22,158	100%	18,093	100%
35%	RI + oSIA	15,753	100%	9,851	100%
50%	RI + oSIA	3,549	99%	602	99%
75%	RI + oSIA	1	14%	1	14%

Sensitivity analysis – different R_0 assumptions

As the true value of R_0 for polio is unknown and depends on geographical settings, sanitation and hygiene, and age. In the main analysis, we assume an R_0 of 3, which is in line with other research and the target population of children under five years of age living in an LMIC in Africa. However, in the sensitivity analysis below (Appendix Table 5) we explore the average number of expected AFP cases over five years and the probability of an outbreak if R_0 = 6. As shown in Appendix Table 5, when RI coverage >50%, a higher R_0 only increases the probability of an outbreak slightly in the annual pSIA strategy but has a bigger effect on outbreak probability for the biannual pSIA and RI+oSIA strategies.

*Appendix Table 5. Expected number of AFP cases and expected probability of an outbreak under different R_0 assumptions. Expected AFP cases were calculated by taking the average number of AFP cases across all stochastic model simulations that had **at least one AFP case.***

RI coverage	SIA strategy	R_0 = 3		R_0 = 6	
		Average number of expected AFP cases over 5 years	Expected probability of an outbreak	Average number of expected AFP cases over 5 years	Expected probability of an outbreak
25%	RI + oSIA + annual pSIA	176	88%	16,379	100%
50%	RI + oSIA + annual pSIA	1	20%	3,837	100%
75%	RI + oSIA + annual pSIA	1	4%	1	19%
25%	RI + oSIA + biannual pSIA	5,564	99%	24,403	100%
50%	RI + oSIA + biannual pSIA	4	67%	9,542	100%
75%	RI + oSIA + biannual pSIA	1	6%	4	68%
25%	RI + oSIA	22,158	100%	37,069	100%
50%	RI + oSIA	3,549	99%	20,229	100%
75%	RI + oSIA	1	14%	2,046	99%

Sensitivity analysis – different importation rates

When RI coverage exceeds 50%, model assumptions for the importation rate of WPV infection have little effect on the expected number of AFP cases and expected probability of an outbreak across all vaccination strategies. This reiterates the importance of baseline RI coverage, which remains an important underlying factor that greatly influences the number of expected AFP cases and outbreak probability, more so than importation rate or assumptions around the proportion of children reached by SIAs.

Appendix Table 6. Expected number of AFP cases and expected probability of an outbreak if the rate of WPV importation is one importation of WPV infection every year and three importations every year, rates that are under and over the rate used in the main analysis (two importations per year). Expected AFP cases were calculated by taking the average number of AFP cases across all stochastic model simulations that had ***at least one AFP case.***

RI coverage	SIA strategy	1 importation every year		3 importations every year	
		Average number of expected AFP cases over 5 years	Expected probability of an outbreak	Average number of expected AFP cases over 5 years	Expected probability of an outbreak
25%	RI + oSIA + annual pSIA	42	71%	49	96%
50%	RI + oSIA + annual pSIA	1	11%	1	27%
75%	RI + oSIA + annual pSIA	1	2%	1	5%
25%	RI + oSIA + biannual pSIA	5,353	95%	5,363	100%
50%	RI + oSIA + biannual pSIA	4	45%	5	78%
75%	RI + oSIA + biannual pSIA	1	3%	1	8%
25%	RI + oSIA	22,327	99%	22,236	100%
50%	RI + oSIA	3,430	91%	3,399	100%
75%	RI + oSIA	1	9%	1	20%

Section 5: Supporting information

Raw data used to inform proportional differences between pSIA and oSIA costs

*Appendix Table 7. Country level SIA data showing the differences in costs between oSIAs and pSIAs. The rightmost column shows the proportional difference between oSIAs and pSIAs for operational costs. *pSIA cost data was available pre COVID-19 pandemic and given in USD$2019, therefore, estimates have been calculated for USD$2023 assuming 2019$1 = 2023$1.18. oSIA cost data for bOPV has historically been less readily available. Therefore, to estimate the proportional differences between oSIAs and pSIAs, oSIA cost data from campaigns administering novel OPV2 (nOPV2) was used and we assume that while the vaccine costs may differ, the oSIA operational costs are similar.*

Country	bOPV cost (USD$)	pSIA - cost per child $2019	pSIA - cost per child $2023*	oSIA (nOPV) - cost per child $2023	proportional difference - *operational only*
Benin	0.17	0.31	0.37	0.73	2.0
Burkina Faso	0.15	0.27	0.32	0.65	2.0
Cameroon	0.17	0.33	0.39	0.86	2.2
Central African Republic	0.17	1.09	1.29	2.79	2.2
Chad	0.16	0.45	0.53	0.42	0.8
Congo	0.16	0.44	0.52	2.29	4.4
Côte d'Ivoire	0.14	0.15	0.18	0.67	3.8
DR Congo	0.15	0.48	0.57	1.28	2.3
Eritrea	0.18	0.95	1.12	1.00	0.9
Ethiopia	0.17	0.89	1.05	0.56	0.5
Gabon	0.16	0.77	0.91	1.00	1.1
Gambia	0.18	0.60	0.71	0.78	1.1
Ghana	0.18	0.29	0.34	1.32	3.9
Guinea	0.19	0.26	0.31	1.23	4.0
Kenya	0.18	0.59	0.70	1.02	1.5
Liberia	0.20	0.83	0.98	1.58	1.6
Madagascar	0.17	0.37	0.44	0.53	1.2
Malawi	-	-	0.00	1.00	
Mali	0.17	0.24	0.28	0.52	1.8
Mauritania	0.12	0.81	0.96	1.00	1.0
Mozambique	-	-	0.00	0.80	
Niger	0.19	0.36	0.42	0.57	1.3
Nigeria	0.21	0.32	0.38	0.22	0.6
Senegal	0.18	0.29	0.34	0.47	1.4
Sierra Leone	0.16	0.46	0.54	0.92	1.7
South Sudan	0.17	0.78	0.92	1.17	1.3
Sudan	0.15	0.58	0.68	0.65	0.9
Tanzania	0.17	0.93	1.10	1.00	0.9
Togo	0.17	0.27	0.32	0.73	2.3
Uganda	0.18	0.48	0.57	1.00	1.8
Zambia	-	-		2.78	
Zimbabwe	-	-		1.76	
Average	**$0.17**	**$0.52**	**$0.61**	**$1.04**	**$1.7**

Cost-effectiveness plane to interpret incremental costs discussed in main text



Appendix Figure 9. Quadrants comprising a cost effectiveness plane for interpretation of incremental costs and DALYs and outbreaks averted under each vaccination strategy.

References

1. Bandyopadhyay AS, Modlin JF, Wenger J, Gast C. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review. Clin Infect Dis. 2018;67(suppl_1):S35-s41. Epub 2018/10/31. doi: 10.1093/cid/ciy633. PubMed PMID: 30376081; PubMed Central PMCID: PMCPMC6206125.
2. Gao H, Lau EHY, Cowling BJ. Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis. The Journal of Infectious Diseases. 2021;225(4):557-66. doi: 10.1093/infdis/jiab480.
3. Utazi CE, Thorley J, Alegana VA, Ferrari MJ, Takahashi S, Metcalf CJE, et al. Mapping vaccination coverage to explore the effects of delivery mechanisms and inform vaccination strategies. Nat Commun. 2019;10(1):1633. Epub 2019/04/11. doi: 10.1038/s41467-019-09611-1. PubMed PMID: 30967543; PubMed Central PMCID: PMCPMC6456602.
4. Zimmermann M, Hagedorn B, Lyons H. Projection of Costs of Polio Eradication Compared to Permanent Control. The Journal of Infectious Diseases. 2019;221(4):561-5. doi: 10.1093/infdis/jiz488.
5. Portnoy A, Ozawa S, Grewal S, Norman BA, Rajgopal J, Gorham KM, et al. Costs of vaccine programs across 94 low-and middle-income countries. Vaccine. 2015;33:A99-A108.
6. UNICEF. Inactivated Polio Vaccine (IPV) price data [26 April 2023]. Available from: https://www.unicef.org/supply/media/16266/file/IPV-vaccine-prices-14032023.pdf.
7. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019–2029. Risk Analysis. 2021;41(2):364-75.
8. Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. Jama. 2004;292(14):1696-701.
9. UNICEF. Guidance Note on Cold Chain Logistics and Vaccine Management During Polio Supplementary Immunization Activities. UNICEF, New York, NY; 2015.
10. Mvundura M, Hsu J-S, Frivold C, Kristensen D, Boyle S, Zehrung D, et al. Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine. Vaccine: X. 2019;2:100032.
11. Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, et al. The role of older children and adults in wild poliovirus transmission. Proceedings of the National Academy of Sciences. 2014;111(29):10604-9.